This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
Healthcare ETFs in Focus Ahead of Q4 Earnings
by Sweta Killa
With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $68.25 in the latest trading session, marking a -0.44% move from the prior day.
Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon
by Zacks Equity Research
Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon
Will Dividend Stocks be the Hot Stocks of 2019?
by Tracey Ryniec
With growth stocks sputtering to end 2018, investors seem poised to look in a new direction.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $68.52 in the latest trading session, marking a +1.89% move from the prior day.
NASH Space in Focus in 2019 as Firms Look to Diversify
by Zacks Equity Research
NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
by Zacks Equity Research
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $68.56 in the latest trading session, marking a +0.45% move from the prior day.
Gilead (GILD) Collaborates With Yuhan for NASH Candidates
by Zacks Equity Research
Gilead (GILD) collaborates with Korean company Yuhan for the development of NASH treatments.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $61.88, marking a -1.68% move from the previous day.
Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018
by Zacks Equity Research
Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
by Zacks Equity Research
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
by Zacks Equity Research
Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).
Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
by Zacks Equity Research
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija
by Zacks Equity Research
Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.
Immunomedics (IMMU) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead
by Zacks Equity Research
Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.
Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer
by Zacks Equity Research
Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.
Bristol-Myers to Sell French Consumer Health Unit for $1.6B
by Zacks Equity Research
Bristol-Myers (BMY) receives a $1.6 billion offer for its French consumer health unit from Japanese company, Taisho.
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint
by Zacks Equity Research
Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.
Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod
by Zacks Equity Research
Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.